Sesen Bio Inc.

Sesen Bio, Inc. engages in designing, engineering, and developing targeted protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Carisma Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of immunotherapies. It offers chimeric antigen receptor (CAR)-macrophages, a cell therapy platform focusing on the treatment of solid tumors. The company was founded by Michael Klichinsky and Saar Gill in April 2016 and is headquartered in Philadelphia, PA.

BENSALEM, Pa.--(BUSINESS WIRE)---- $SESN #CLASSACTION--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Sesen Bio, Inc. (“Sesen Bio” or the “Company”) (NASDAQ: SESN) securities between December 21, 2020 and August 17, 2021, inclusive (the “Class Period”). Sesen Bio investors have until October 18, 2021 to file a lead plaintiff motion. Investors suffering losses on their Sesen Bio investments are encouraged to contact the Law Offices of Howard G.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Sesen Bio, Inc. (SESN) Investors

LOS ANGELES--(BUSINESS WIRE)---- $SESN #investors--SESN CLASS ACTION NOTICE: The Law Offices of Frank R. Cruz Files Securities Fraud Lawsuit Against Sesen Bio, Inc.

SESN CLASS ACTION NOTICE: The Law Offices of Frank R. Cruz Files Securities Fraud Lawsuit Against Sesen Bio, Inc.

Investors need to pay close attention to Sesen Bio (SESN) stock based on the movements in the options market lately.

Do Options Traders Know Something About Sesen Bio (SESN) Stock We Don't?

LOS ANGELES--(BUSINESS WIRE)---- $SESN #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), announces that it has filed a class action lawsuit in the United States District Court for the Southern District of New York captioned Bibb v. Sesen Bio, Inc.,et al., (Case No. 21-cv-7025) on behalf of persons and entities that purchased or otherwise acquired Sesen Bio, Inc. (“Sesen Bio” or the “Company”) (NASDAQ: SESN) securities between December 21, 2020 and August 17, 2021, inclusive (the “Class Period”). Plaintiff pursue

SESN CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Sesen Bio, Inc.

NEW YORK--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Sesen Bio, Inc. (“Sesen” or the “Company”) (NASDAQ: SESN) on behalf of Sesen stockholders. Our investigation concerns whether Sesen has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. Sesen is a late-stage clinical company advancing targeted fusion protein ther

SESEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Sesen Bio, Inc. on Behalf of Sesen Stockholders and Encourages Investors to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $SESN #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, continues its investigation on behalf of Sesen Bio, Inc. (“Sesen Bio” or the “Company”) (NASDAQ: SESN) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Sesen Bio investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your co

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Its Investigation of Sesen Bio, Inc. (SESN) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)---- $SESN #CLASSACTION--Law Offices of Howard G. Smith continues its investigation on behalf of Sesen Bio, Inc. (“Sesen Bio” or the “Company”) (NASDAQ: SESN) investors concerning the Company's possible violations of federal securities laws. On August 13, 2021, Sesen Bio announced that the FDA declined to approve its Biologics License Application (“BLA”) for Vicineum in its current form. The FDA provided certain “recommendations specific to additional clinical/statistical data and analys

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Its Investigation of Sesen Bio, Inc. (SESN) on Behalf of Investors

Boston, Massachusetts--(Newsfile Corp. - August 19, 2021) - Block & Leviton is investigating Sesen Bio, Inc. (NASDAQ: SESN) for potential securities law violations. Investors who have lost money in their Sesen Bio investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/sesn.What is this all about?During trading hours on August 13, 2021, Sesen Bio announced that the U.S. Food and Drug Administration (FDA) declined to...

SESEN BIO INVESTIGATION: Block & Leviton Investigates Sesen Bio For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Sesen Bio, Inc. (NASDAQ: SESN) resulting from allegations that Sesen Bio may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Sesen Bio securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

EQUITY ALERT: Rosen Law Firm Encourages Sesen Bio, Inc. Investors with Losses to Inquire About Class Action Investigation – SESN

RADNOR, Pa., Aug. 19, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP is currently investigating potential violations of the federal securities laws on behalf of shareholders of Sesen Bio, Inc. (NASDAQ: SESN) ("Sesen").

Investigation Alert: Kessler Topaz Meltzer & Check, LLP is Investigating Securities Fraud Claims on Behalf of Sesen Bio, Inc. (NASDAQ: SESN) Investors

LOS ANGELES--(BUSINESS WIRE)---- $SESN #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Sesen Bio, Inc. (“Sesen Bio” or the “Company”) (NASDAQ: SESN) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Sesen Bio investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities l

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Sesen Bio, Inc. (SESN) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)---- $SESN #CLASSACTION--Law Offices of Howard G. Smith announces an investigation on behalf of Sesen Bio, Inc. (“Sesen Bio” or the “Company”) (NASDAQ: SESN) investors concerning the Company's possible violations of federal securities laws. On August 13, 2021, Sesen Bio announced that the U.S. Food and Drug Administration (“FDA”) declined to approve its Biologics License Application for its bladder cancer treatment Vicineum its current form. The FDA provided certain “recommendations spec

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Sesen Bio, Inc. (SESN) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)---- $SESN #investors--The Law Offices of Frank R. Cruz Announces Investigation of Sesen Bio, Inc. (SESN) on Behalf of Investors

The Law Offices of Frank R. Cruz Announces Investigation of Sesen Bio, Inc. (SESN) on Behalf of Investors

Sesen Bio Inc (NASDAQ: SESN) said that it was not expecting a CRL from the FDA for its bladder cancer candidate Vicineum.  But the rejected filing includes several violations and investigator misconduct, STAT News reported.

Sesen Bio's Bladder Cancer Trial Wrecked By Misconduct: Stat News

Atlanta, Georgia--(Newsfile Corp. - August 18, 2021) - Holzer & Holzer, LLC is investigating whether Sesen Bio, Inc. ("Sesen" or the "Company") (NASDAQ: SESN) complied with federal securities laws. On August 13, 2021, SESN received a Complete Response Letter from U.S. Food and Drug Administration ("FDA") and announced that the FDA had declined to approve the Biologics License Application for Vicineum. On this news, the price of the Company's stock plummeted.If you purchased Sesen...

SHAREHOLDER ALERT: Investigation of Sesen Bio, Inc. Announced by Holzer & Holzer, LLC

New York, New York--(Newsfile Corp. - August 17, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Sesen Bio, Inc. ("Sesen Bio" or the "Company") (NASDAQ: SESN). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Sesen Bio and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sesen Bio, Inc. - SESN

Some investors clearly believe all is not lost with the company's leading pipeline drug.

Why Sesen Bio Stock Bounced Back Sharply Today

OKLAHOMA CITY--(BUSINESS WIRE)-- #Biotechnology--Federman & Sherwood announces an investigation into Sesen Bio (NASDAQ: SESN). The complaint will allege violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series of material or false misrepresentations to the market which had the effect of artificially inflating the market price during the Class Period, which is August 9, 2021 through August 13, 2021. To lea

Federman & Sherwood Announces an Investigation into Sesen Bio

The FDA dashes the company's hopes for its core pipeline drug...at least for now.

Why Sesen Bio Stock Fell off a Cliff Monday

Sesen's (SESN) biologics license application filed for Vicineum to treat BCG-unresponsive non-muscle invasive bladder cancer fails to secure approval. The stock declines resultantly.

Sesen's (SESN) Bladder Cancer Drug Vicineum Gets CRL From FDA

Sesen Bio (SESN) stock is taking a beating on Monday following a letter from the U.S. Food and Drug Administration (FDA). The post SESN Stock: Why Sesen Bio Is Getting Slammed Today appeared first on InvestorPlace.

SESN Stock: Why Sesen Bio Is Getting Slammed Today

Sesen Bio Inc (NASDAQ: SESN) is trading significantly lower Monday after the U.S. Food and Drug Administration issued a Complete Response Letter for the company's bladder cancer candidate Vicineum. The FDA determined that it cannot approve Sesen Bio's Biologics License Application for Vicineum in its present form and provided recommendations specific to additional clinical and statistical data and analyses.

Why Sesen Bio Shares Are Trading Lower Today

The FDA issued a Complete Response Letter (CRL) to Sesen Bio Inc's (NASDAQ: SESN) bladder cancer candidate Vicineum. The Company acquired the antibody-drug conjugate in the buyout of Viventia back in 2016.

Sesen Bio Stock Crashes As FDA Shoots Down Its Bladder Cancer Pitch

The shares of Sesen Bio Inc (NASDAQ: SESN) fell by over 10% pre-market. This is why it happened.

Sesen Bio Shares Fell Over 10% Pre-Market: Why It Happened

SESN stock is plummeting today. The company was unexpectedly denied approval for its bladder cancer-treatment drug, disappointing investors.

News for Sesen Bio Inc. Stock (SESN)